Screener
CytomX Therapeutics CTMX Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by CytomX Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: CytomX Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-337950
FAQ
- What is CytomX Therapeutics's total liabilities?
- CytomX Therapeutics (CTMX) reported total liabilities of $79.16M in Q2 2026.
- How has CytomX Therapeutics's total liabilities changed year-over-year?
- CytomX Therapeutics's total liabilities increased by 43.5% year-over-year, from $55.15M to $79.16M.
- What is the long-term trend for CytomX Therapeutics's total liabilities?
- Over 5 years (2020 to 2025), CytomX Therapeutics's total liabilities has grown at a -32.2% compound annual growth rate (CAGR), from $366.44M to $52.56M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about CytomX Therapeutics's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude